Three top-ranked drugmakers are among IBD’s 10 leading global growth stocks. One is in buying range. Jazz Pharmaceuticals (JAZZ) appears to have gained some traction after a disappointing breakout Nov. 5, when the stock cleared its buy point only to reverse lower in heavy volume. Jazz, which relies heavily on sales of narcolepsy drug Xyrem, has since recovered.